1. HOME
  2. en_home
  3. news
  4. V5med and Clairvo Technologies to Enter into an Business Alliance Agreement

V5med and Clairvo Technologies to Enter into
an Business Alliance Agreement
on Medical Device Programs Assisting in the Detection of
Nodules from Chest CT Images

April 17, 2024

Clairvo Technologies Co., Ltd. (Headquarters: Chiyoda, Tokyo; CEO: Riichi Yamada, hereafter "Clairvo") has entered into an exclusive business alliance agreement with V5med Inc. (Headquarters: Hsinchu City, Taiwan; CEO: Michael Huang, hereafter “V5med”).

 

With the conclusion of the agreement, V5med and Clairvo aim to obtain necessary regulatory approvals to market a product in Japan.

The medical device program developed by V5med is a chest CT imaging diagnostic support software.

In Taiwan, the product has already obtained TFDA Class II certificates.

 

The product assists in the detection of nodules in low-dose CT images, providing information not only on nodule location, but also on nodule size, volume, and characteristics.

In addition to this information, the report generation support function contributes to the efficiency of image reading and the shortening of examination time.[1]

V5 Product小.jpg 

Based on the company's philosophy of "Innovation For Healthcare", Clairvo, together with V5med, aims to contribute to people's healthy lives by distributing this product in Japan and contributing to the reduction of workloads of radiologists and doctors.

 

【About V5med】

V5 Technologies was established in 2014 with a primary focus on Medical Image AI. Leveraging cutting-edge AI technology, V5 Technologies collaboratively partnered with prestigious institutions such as Taipei Veterans General Hospital, National Taiwan University Hospital, and the Taiwan Lung Cancer Society. Together, they spearheaded the development of V5 Lung AI, an advanced lung cancer screening computer-aided detection (CAD) system.
V5med_(英文_-_LOGO)_01-24-2024-2.png

 

[1] “Artificial Intelligence Assisted Computational Tomographic Detection of Lung Nodules for Prognostic Cancer Examination: A Large-Scale Clinical Trial “Heng-Sheng Chao, et al. Biomedicines 2023, 11, 147.

Our press releases are intended to inform our stakeholders about our company in a fair and timely manner. While they may contain information about products or diseases, they are not intended as advertisements, promotions, purchase recommendations, or customer inducements.




 

Contact

To request information or make an inquiry, please contact us using the e-mail form below.